AB141813
Ivermectin, Positive allosteric modulator of alpha7 nicotinic acetylcholine receptors
Be the first to review this product! Submit a review
|
(1 Publication)
MW 875.1 Da, Purity >96%. Positive allosteric modulator of α7 neuronal nicotinic acetylcholine receptor. Allosteric effector of P2X4 receptors. Antihelmintic. Modulates glutamate- and GABA-activated chloride channels. Potentiates glycine-gated currents at low concentrations (30 nM).
1 Images
- Chemical Structure
Lab
Chemical Structure - Ivermectin, Positive allosteric modulator of alpha7 nicotinic acetylcholine receptors (AB141813)
2D chemical structure image of ab141813, Ivermectin, Positive allosteric modulator of alpha7 nicotinic acetylcholine receptors
Product details
This product is manufactured by BioVision, an Abcam company and was previously called 2721 Ivermectin. 2721-250 is the same size as the 250 mg size of ab141813.
Properties and storage information
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
Storage information
Store under desiccating conditions|The product can be stored for up to 12 months
Publications (1)
Recent publications for all applications. Explore the full list and refine your search
Microorganisms 8: PubMed32183205
2020
Ivermectin Inhibits Bovine Herpesvirus 1 DNA Polymerase Nuclear Import and Interferes with Viral Replication.
Applications
Unspecified application
Species
Unspecified reactive species
Sohail Raza,Farzana Shahin,Wenjun Zhai,Hanxiong Li,Gualtiero Alvisi,Kui Yang,Xi Chen,Yingyu Chen,Jianguo Chen,Changmin Hu,Huanchun Chen,Aizhen Guo
Product promise
We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com